Field Trip Health Debuts On Nasdaq With Average Performance, Looks To Expand Footprint Of Psychedelics Clinics

Field Trip Health FTRP FTRP made its Nasdaq debut on Thursday, becoming the fifth company in the psychedelics space to receive a welcome by Wall Street this year.

The company, led by CEO Joseph de Moral, is establishing a footprint of psychedelics-assisted psychotherapy clinics across North America and Europe, with a goal of providing mental health treatment with psychedelics molecules as they come into legality.

“Listing on the leading securities exchange for biotech companies will enable more investors both in the U.S. and globally to support Field Trip as we advance our ground-breaking work in the psychedelics industry,” Dr. Ryan Yermus, Field Trip’s chief clinical officer said.

For the time being, Field Trip is offering treatment using Ketamine, a legal psychedelic-like drug originally approved as an anesthetic. The company currently owns and operates six clinics with locations in New York, LA, Chicago, Huston, Atlanta, Toronto and Amsterdam.

Amsterdam is the company’s only European location, where psilocybin treatment is currently offered in the form of psilocybin truffles, which are allowed in the Netherlands due to a legal loophole around the cultivation of psilocybin mushrooms.

Big Plans For The Near Future: In an interview with Benzinga, co-founder and executive chairman Ronan Levy stated plans to open up to 75 clinics across North America by 2024.

The executive mentioned the progress being made with the development of FT-104, a novel psychedelic molecule developed by the company, which is currently undergoing GMP production in preparation for Phase 1 studies.

FT-104 is a proprietary psilocybin analog, currently in preclinical research, that could offer improved therapeutic potential to naturally-occurring psilocybin.

Just Another Day of Trading For Field Trip: Field Trip's stock was listed on the Nasdaq Global Select Market, which is considered the highest-ranking tier in the exchange. Nevertheless, the markets didn’t respond with much enthusiasm.

Field Trip's shares dropped down from $6.22 at market open to $5.55 at noon Thursday. Prices slowly picked up during the afternoon, reaching $5.72 at the time of this writing with a trading volume that had not yet reached the average of approximately 65,000 shares.

Courtesy photo.

Posted In: psychedelicsCannabisMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.